Nanobiotix S.A.
NASDAQ · us_market
No AI insight generated yet for this ticker.
Nanobiotix S.A. operates as a clinical-stage biotechnology that focuses on developing product candidates for the treatment of cancer and other unmet medical needs. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck, liver, prostate, pancreatic, esophageal, rectal, and non-small cell lung cancer. The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in China, South Korea, Singapore, and Thailand. Nanobiotix S.A. was incorporated in 2003 and is based in Paris, France.
| Report Date | EPS Estimate | EPS Actual | Surprise |
|---|---|---|---|
| 2026-09-29upcoming | — | — | — |
| 2022-04-07 | -0.59 | -0.16 | +73.03% |
| 30d | 90d | YTD | 1y | |
|---|---|---|---|---|
| NBTX | +15.03% | +32.11% | +74.74% | +885.37% |
| XLV | +2.97% | -4.64% | -3.44% | +12.69% |
| Alpha (stock − sector) | +12.07% | +36.75% | +78.18% | +872.68% |